Printer Friendly

A patient with multiple IRIS.

TThe immune reconstitution inflammatory syndrome (IRIS) is a frequent early complication of antiretroviral therapy (ART), particularly in patients who commence ART with low CD4 counts and established opportunistic infections. IRIS results from a pathological inflammatory response to pre-existing infective, host or other antigens, alive or dead, causing clinical deterioration in HIV-infected patients after initiating ART. (1) A case definition for IRIS is shown in Table I. The most common forms of IRIS described occur in association with mycobacterial and herpesvirus infections. (3) We describe here a patient who presented with IRIS in association with tuberculosis (TB), then cryptococcosis, and later varicella zoster virus (VZV).

A 38-year-old man from the Democratic Republic of Congo was diagnosed with disseminated TB on the basis of a sputum culture which grew Mycobacterium tuberculosis. The isolate was sensitive to isoniazid and rifampicin. A fine-needle aspirate of a peripheral lymph node was also positive for acid-fast bacilli. His chest radiograph from this time is shown in Fig. 1. The patient was commenced on regimen 1 TB treatment. An HIV test was reactive and his CD4 count was 9 cells/[micro]l. Good adherence to TB treatment was reported.

He was referred for ART, but the clinic delayed initiation because of social problems. Three months later he was readmitted with cryptococcal meningitis. Cerebrospinal fluid (CSF) results are shown in Table II. He received 5 days of intravenous amphotericin B, followed by oral fluconazole 400 mg daily. His headache and vomiting resolved on this treatment.

Two weeks after the cryptococcal diagnosis he was started on ART (stavudine, lamivudine and efavirenz). Fluconazole, TB treatment and co-trimoxazole were continued. Ten days later he presented with a 4-day history of severe right-sided pleuritic chest pain and fevers. No cough or headaches were reported. He had lost 6 kg in 2 weeks and had a temperature of 38[degrees]C. Chest auscultation revealed crepitations bibasally. No lymph node enlargement was detected. Blood oxygen saturation was normal. The chest radiograph from this time is shown in Fig. 2. A diagnosis of TB-IRIS was made, but he was also given antibiotics to cover the possibility of bacterial chest infection. One week later he reported symptomatic improvement, but still had mild chest pain, a tachycardia and a low-grade fever.

[FIGURE 1 OMITTED]

[FIGURE 2 OMITTED]

Four weeks after starting ART he was re-admitted with a 5-day history of severe headaches and vomiting. He was apyrexial and had lost 2 kg since his last visit. He had new axillary and submental adenopathy. Terminal neck stiffness was present but fundoscopy, visual fields and eye movements were normal. His CD4 count had risen to 30 cells/[micro]l. A lumbar puncture had an opening pressure of 56 cm [H.sub.2]O. CSF results are shown in Table II.

A diagnosis of cryptococcal meningitis IRIS (CM-IRIS) was made. He was treated with amphotericin B while awaiting a CSF fungal culture result to exclude treatment failure as a cause of his symptoms. Prednisone at 1.5 mg/kg for 2 weeks was added. He also had regular lumbar punctures to decrease his raised intracranial pressure. His CSF fungal culture was negative after 2 weeks' incubation. His symptoms resolved on this treatment.

Two months after starting ART he developed a VZV rash involving the left [V.sub.1] dermatome of his face. The cornea was not affected. Acyclovir 800 mg 5 times daily was prescribed and the rash resolved on this treatment.

DISCUSSION

This patient had several of the documented risk factors for IRIS: opportunistic infections prior to ART, disseminated TB, low baseline CD4 count and ART initiation soon after CM diagnosis. (4-7)

He presented with three episodes of IRIS in the first 2 months of ART, each related to different infections. Within 2 weeks of commencing ART the patient was diagnosed with TB-IRIS. This diagnosis was made on the basis of recurrent respiratory symptoms and fever, and particularly because the chest radiograph showed worsening features of TB. TB-IRIS typically presents 1-4 weeks after ART initiation. (5,8)

The most common manifestations of TB-IRIS are fever and recurrence of TB symptoms, as in our patient. A wide range of other manifestations have been described and include worsening radiographic pulmonary infiltrates, lymph node enlargement, cold abscesses, serous effusions, hepatic and splenic involvement and meningitis. (9)

When this patient presented with TB-IRIS, his chest radiograph demonstrated bilateral lower zone linear opacifications and an increase in size of mediastinal lymph nodes. Radiographic imaging plays an important role in diagnosing and monitoring TB-IRIS. Radiographically, TB-IRIS manifests as new or increased pulmonary parenchymal disease, lymphadenopathy or pleural effusions alone or in combination. It is not uncommon for patients with advanced immunosuppression and TB undergoing a TB-IRIS episode with radiological worsening to have had a normal chest radiograph at initial TB diagnosis. Conversely, patients presenting with clinically significant signs and symptoms of TB-IRIS do not always manifest with radiographic worsening. In one study the mean time from beginning of radiographic worsening to beginning of improvement was 7 weeks for pulmonary disease, 13 weeks for adenopathy, and 4 weeks for pleural effusions. (10)

This patient's presentation with a lymphocytic meningitis 4 weeks after starting ART was diagnosed as CM-IRIS. This is often associated with raised intracranial pressure, as in this case, and in one study the median duration from ART to CM-IRIS was 28 days. (7) The finding of a negative fungal culture excluded cryptococcal treatment failure and supported the diagnosis of CM-IRIS. The increase in white cell count in the CSF compared with initial diagnosis, as in this case, was found to occur in CM-IRIS in the study mentioned above. (7) Treatment of CM-IRIS involves therapeutic lumbar punctures to relieve raised intracranial pressure and corticosteroids in severe or refractory cases, although there is no prospective evidence regarding the management of any form of IRIS. (11)

His presentation with a VZV rash 2 months after starting ART was probably also an IRIS event, or could have been related to the corticosteroid therapy given earlier. Although this was a typical monodermatomal presentation of this infection, the finding that patients are at a 5-fold higher risk of presenting with VZV in the first 4 months of ART (12) suggests that immune reconstitution is playing a role in such presentations. Management is with acyclovir.

Currently IRIS is a diagnosis of exclusion, as there is no confirmatory test. Important exclusions include treatment failure due to antimicrobial resistance or poor adherence, another infection or drug toxicity. A thorough patient history is important as initial improvement on specific treatment for an opportunistic infection followed by deterioration after ART initiation is characteristic of IRIS. IRIS has resource implications in terms of the increased need for investigations and treatment interventions, as demonstrated by our patient's repeated admissions. This case highlights the risks faced during immune reconstitution in patients who commence ART with advanced immunosuppression.

[ILLUSTRATION OMITTED]

We wish to thank Professor Hillel Goodman for his assistance in reporting the radiographs.

REFERENCES

(1.) Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24: 549-570.

(2.) Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57: 167-170.

(3.) French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4: 16-21.

(4.) Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type-1 infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-1712.

(5.) Lawn SD, Myer L, Bekker L, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.

(6.) Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F; French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-1049.

(7.) Shelburne SA 3rd, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 1049-1052.

(8.) Breen RAM, Smith CJ, Bettison H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-707.

(9.) Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373.

(10.) Fishman JE, Saraf-lavi E, Narita M, Hollender ES, et al. Pulmonary tuberculosis in AIDS patients: Transient chest radiographic worsening after initiation of antiretroviral therapy. AJR 2000; 174: 43-49.

(11.) Murdoch DM, Venter WDF, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4: 9.

(12.) Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27: 1510-1513.

Valerie Asselman (1), MB ChB, DTM&H, Dip HIV Man (SA)

Graeme Meintjes (1,2), MB ChB, MRCP, FCP (SA), Dip HIV Man (SA)

(1) HIV Service, G F Jooste Hospital, Cape Town

(2) Department of Medicine, University of Cape Town
TABLE I. CRITERIA FOR DIAGNOSIS OF IRIS PROPOSED BY
SHELBURNE AND COLLEAGUES (2)

* HIV-positive

* Receiving highly active antiretroviral therapy (HAART)

 * Decrease in HIV-1 RNA level from baseline

 * Increase in CD4+ cells from baseline (may lag behind HIV-1
 RNA decrease)

* Clinical symptoms consistent with inflammatory process

* Clinical course not consistent with:

 * Expected course of previously diagnosed opportunistic
 infection

 * Expected course of newly diagnosed opportunistic
 infection

 * Drug toxicity

TABLE II. CSF RESULTS AT CM AND CM-IRIS DIAGNOSIS

Timing of LP CM diagnosis CM-IRIS diagnosis

Polymorphs (cells/[micro]l) 1 5
Lymphocytes (cells/[micro]l) 3 45
Erythrocytes (cells/[micro]l) 215 187
Glucose (mmol/l) 3 2.8
Protein (g/l) 1 1.5
VDRL Negative Negative
Cryptococcal latex >1:4 (not 1:256
antigen test (CLAT) quantified)
Cryptococcus culture Positive Negative
COPYRIGHT 2007 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CASE STUDY; immune reconstitution inflammatory syndrome
Author:Asselman, Valerie; Meintjes, Graeme
Publication:Southern African Journal of HIV Medicine
Article Type:Case study
Geographic Code:6SOUT
Date:Mar 22, 2007
Words:1662
Previous Article:AIDS: a Darwinian event?
Next Article:CPD questions: Journal 33.
Topics:


Related Articles
Effective HAART can trigger immune reconstitution.
Early mortality among patients with HIV-associated tuberculosis in Africa: implications for the time to initiation of antiretroviral treatment.
Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons.
Guillain-Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection.
HIV infection and the kidney.
Maternal outcomes following introduction of antiretroviral therapy in the public sector: a prospective study at a tertiary hospital in the Eastern...
Cavitation of the Ghon focus in an HIV-infected infant who acquired tuberculosis after the initiation of HAART.
HIV/TB: when is it safe to start HAART?
Immune reconstitution inflammatory syndrome in children.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters